Weekly Research Analysts’ Ratings Updates for Qiagen (QGEN)

Several analysts have recently updated their ratings and price targets for Qiagen (NASDAQ: QGEN):

  • 11/2/2018 – Qiagen was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/31/2018 – Qiagen had its price target raised by analysts at Morgan Stanley from $39.00 to $41.00. They now have an “overweight” rating on the stock.
  • 10/30/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Commerzbank AG.
  • 10/30/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Barclays PLC.
  • 10/30/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Deutsche Bank AG.
  • 10/22/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Commerzbank AG.
  • 10/19/2018 – Qiagen was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 10/11/2018 – Qiagen was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 10/10/2018 – Qiagen had its price target raised by analysts at Morgan Stanley from $38.00 to $39.00. They now have an “overweight” rating on the stock.
  • 10/5/2018 – Qiagen was given a new $44.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 9/17/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Commerzbank AG.
  • 9/13/2018 – Qiagen was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

QGEN traded down $1.11 during trading on Tuesday, hitting $35.87. The company’s stock had a trading volume of 2,816,500 shares, compared to its average volume of 1,007,578. Qiagen NV has a one year low of $30.20 and a one year high of $39.45.

Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Monday, October 29th. The company reported $0.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.02. The business had revenue of $377.90 million during the quarter, compared to the consensus estimate of $380.11 million. During the same quarter in the previous year, the business posted $0.32 earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. LPL Financial LLC purchased a new stake in shares of Qiagen in the first quarter worth $316,000. Allianz Asset Management GmbH increased its stake in shares of Qiagen by 2.7% in the first quarter. Allianz Asset Management GmbH now owns 187,882 shares of the company’s stock worth $6,071,000 after purchasing an additional 5,000 shares in the last quarter. Clinton Group Inc. increased its stake in shares of Qiagen by 180.7% in the second quarter. Clinton Group Inc. now owns 22,190 shares of the company’s stock worth $802,000 after purchasing an additional 14,284 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Qiagen by 58.2% in the second quarter. Assenagon Asset Management S.A. now owns 1,089,825 shares of the company’s stock worth $39,457,000 after purchasing an additional 400,828 shares in the last quarter. Finally, Hardman Johnston Global Advisors LLC increased its stake in shares of Qiagen by 2.9% in the second quarter. Hardman Johnston Global Advisors LLC now owns 3,758,339 shares of the company’s stock worth $135,902,000 after purchasing an additional 106,960 shares in the last quarter. Institutional investors and hedge funds own 62.23% of the company’s stock.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Further Reading: Growth Stocks, What They Are, What They Are Not

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply